3 completed, 2 active not recruiting, 2 withdrawn, 1 not yet recruiting. 6 Phase 4, 4 Phase 2, 1 Early Phase 1, 1 Phase 3.
Follow Giapreza: new trials by email Literature Review of Giapreza trials Research Report on Giapreza
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Angiotensin II for Post Cardiac Surgery Vasoplegia (ANGII_V) Angiotensin II (Giapreza®) - Vasoplegic Shock, Cardiopulmonary Bypass | Phase 4 | Not yet recruiting | Methodist Healthcare System of San Antonio | 329 | 2026-07-01 | 2026-06-26 |
| Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT) Angiotensin II (Giapreza®), Yttrium-90 radioembolization - Liver Cancer (Locally Advanced or Metastatic), Liver Cancer Adult | Phase 2 | Recruiting | Niek Wijnen | 15 | 2026-01-01 | 2026-03-30 |
| Comparison of Angiotensin II to Standard Dose Vasopressors on Change in Arterial Elastance Giapreza - Septic Shock, Cirrhosis | Early Phase 1 | Active not recruiting | The Cleveland Clinic | 30 | 2024-11-15 | 2026-05-05 |
| Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock Angiotensin II and hydrocortisone sodium succinate - Septic Shock, Shock | Phase 4 | Unknown | Kingman Regional Medical Center | 50 | 2023-12-04 | 2024-05-23 |
| Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock Angiotensin II - Septic Shock, Vasodilatory Shock | Phase 4 | Completed | University of New Mexico | 42 | 2023-04-17 | 2026-07-02 |
| Angiotensin II in Liver Transplantation Angiotensin II, Saline - Liver Transplant; Complications, Vasoplegia | Phase 2 / Phase 3 | Active not recruiting | University of California, San Francisco | 50 | 2022-06-28 | 2026-03-20 |
| Angiotensin II for Distributive Shock Angiotensin II, Placebo - Distributive Shock | Phase 4 | Terminated | Northwestern University | 2 | 2022-06-01 | 2026-04-13 |
| Angiotensin II vs. Vasopressin in Septic Shock Angiotensin II, Vasopressin - Septic Shock | Phase 4 | Withdrawn | University of New Mexico | 2022-01-03 | 2024-03-15 | |
| Angiotensin 2 for Hepatorenal Syndrome Angiotensin II, Midodrine, Octreotide - Hepatorenal Syndrome, Cirrhosis | Phase 2 | Withdrawn | University of California, Los Angeles | 2021-07-01 | 2024-03-06 | |
| Angiotensin II in General Anesthesia Angiotensin II - Hypertension | Phase 4 | Completed | Wake Forest University Health Sciences | 32 | 2019-10-03 | 2025-08-24 |
| A Study of LJPC-501 in Pediatric Patients With Hypotension Angiotensin II - Catecholamine-resistant Hypotension (CRH), Distributive Shock | Phase 2 | Completed | La Jolla Pharmaceutical Company | 2 | 2018-02-11 | 2018-08-07 |
Shock, Septic (4) · Acute Kidney Injury (3) · Fibrosis (3) · Vasoplegia (3) · Sepsis (2) · Carcinoma, Hepatocellular (1) · Diabetes Insipidus (1) · Hepatorenal Syndrome (1) · Hypertension (1) · Hypotension (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1) · Shock (1) · Systemic Inflammatory Response Syndrome (1)
University of New Mexico (2) · Kingman Regional Medical Center (1) · La Jolla Pharmaceutical Company (1) · Methodist Healthcare System of San Antonio (1) · Niek Wijnen (1) · Northwestern University (1) · The Cleveland Clinic (1) · University of California, Los Angeles (1) · University of California, San Francisco (1) · Wake Forest University Health Sciences (1)
United States (8) · Netherlands (1)
Joao P Teixeira, MD (2) · Nathan D Nielsen, MD MSc (2) · Choy Lewis, MD (1) · Michael P Bokoch, M.D., Ph.D. (1) · Rohesh Fernando, MD (1) · Siddharth Dugar, M.D. (1) · Tyson Dietrich, PharmD (1)
2025 (1), UL1TR001449 (1)